cardiomyocytes

[Stem Cell Reports] Exposure of human pluripotent stem cell-derived cardiomyocytes and primary endothelial cells to SARS-CoV-2 identified significant differences in protein coding genes involved in immunity, viral response, and cardiomyocyte/endothelial structure.

[Biochemical Pharmacology] The authors discuss patient-specific in vitro models of genetic diseases of the heart based on iPSCs, that address questions surrounding how different variants in the SCN5A gene produce different clinical syndromes.

[Journal of the American Heart Association] Researchers investigated the functional mechanism of exosomal microRNA‐96 derived from bone marrow mesenchymal stem cells in myocardial toxicity induced by doxorubicin.

[Scientific Reports] The authors demonstrated that protocatechuic acid treatment significantly downregulated the expression of cardiac hypertrophic markers, cardiomyocyte size, heart weight to body weight ratio, cross-sectional area, and thickness of left ventricular septum and posterior wall.

[Rocket Pharmaceuticals, Inc.] Rocket Pharmaceuticals, Inc. announced that the US FDA has lifted the clinical hold on the company’s Phase I clinical trial of RP-A501 for the treatment of Danon Disease, allowing patient enrollment to resume. RP-A501 is an investigational gene therapy product being developed for Danon Disease and the first potential gene therapy for monogenic heart failure.

[Cardiovascular Research] The authors identified CARdiomyocyte Maturation-Associated lncRNA (CARMA), a conserved long non-coding RNA controlling cardiomyocyte differentiation and maturation in human ESCs.